Successful Outcomes of Wound Treatment With Kerecis Fish Skin Grafts in Sweden
REYKJAVIK, ICELAND and STOCKHOLM, SWEDEN--(Marketwired - Feb 29, 2016) - A wound that had not healed after 20 years of treatment healed after only two months of treatment with Kerecis Omega3 fish skin. A patient who had been scheduled for amputation escaped that outcome when her chronic wound started healing after treatment with the Kerecis fish-skin graft.
These are some of the dramatic results of Swedish medical tests of the fish-skin grafts. When grafted onto damaged human tissue and skin, the patented Kerecis Omega3 material recruits the body's own cells, which are then incorporated into the damaged area and ultimately are converted into functional, living tissue.
Stockholm County Innovation and the Department of Dermatology at Danderyds Hospital in Stockholm recently announced the successful outcome of usage tests of the Kerecis Omega3 Wound treatment product on seven patients with severe chronic leg wounds. The patients' wounds had not healed with traditional treatments. Stockholm County Innovation is an organization tasked with the purpose of bringing new innovative technologies into the hospitals of Stockholm County, which has a population of more than 2 million people.
One patient had been treated for a chronic leg wound for 20 years. After being treated with the Kerecis fish-skin graft, the wound healed in only two months. Another patient saw a 6-year-old chronic wound heal in a matter of months.
Several other hospitals in Sweden are also testing the Kerecis Omega3 Wound graft on selected, hard-to-heal wounds.
"These were some of our most difficult cases and the results for the patients were very good," said Fredrik Correa, the physician in charge of the project at Danderyds. "Many of these chronic, hard-to-heal wounds showed recovery and accelerated healing using the fish skin. It is clear to us that Kerecis Omega3 Wound accelerated and helped the wounds heal faster," he added.
"We are used to seeing great results from our product, especially with diabetic wounds," said Dr. Baldur Tumi Baldursson, dermatologist and medical director at Kerecis. "A recent case in the UK had a 76-year-old woman escape a scheduled, lower-leg amputation when her leg ulcers healed with the Kerecis graft, a particularly gratifying result.
"We believe this treatment has the potential to change the standard of care for the treatment of chronic and hard-to-heal wounds, improving patients' lives and providing long-term economic benefits for the health sector," he added.
Kerecis develops regenerative technologies based on fish skin that contains Omega3 polyunsaturated fatty acids. Kerecis Omega3 is acellular, intact fish skin used to regenerate damaged human tissue. The Kerecis technology provides a natural structure that contains proteins and fats (including Omega3) and other skin elements. Cells and stem cells migrate into the Kerecis material where they create new tissue to seal the wound. Research has shown that cells proliferate faster in this structure than in other materials such as mammalian-sourced materials.
The initial Kerecis product, Kerecis Omega3 Wound, has been approved by the FDA and European regulatory authorities for wound healing. The technology is patented in the United States, and patents are pending in multiple countries.
Production takes place in the Kerecis manufacturing facilities in Iceland. For more information, visit www.kerecis.com. Distributor inquiries are welcome.